Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC) Meeting Abstract
| Authors: | Escudier, B.; Motzer, R. J.; Rini, B. I.; Powles, T.; McDermott, D. F.; Suarez, C.; Bracarda, S.; Stadler, W. M.; Donskov, F.; Gurney, H.; Oudard, S.; Uemura, M.; Lam, E. T.; Grüllich, C.; Ding, B.; Khaznadar, T.; Quach, C.; Piault, E.; Schiff, C.; Atkins, M. B. |
| Abstract Title: | Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC) |
| Meeting Title: | 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2018 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-20 |
| Start Page: | 243s |
| Language: | English |
| ACCESSION: | WOS:000442916002038 |
| DOI: | 10.1200/JCO.2018.36.15_suppl.4511 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4511 -- Source: Wos |
